A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

This study tests whether toripalimab (a PD-1 immunotherapy drug) given after surgery and radiation/chemotherapy helps prevent head and neck squamous cell cancer from coming back in patients with locally advanced disease who have certain risk factors. **You may be eligible if...** - You had surgery for locally advanced head and neck squamous cell cancer with high-risk features - You completed postoperative chemoradiation no more than 2 months ago - You are 18–70 years old in good general health (ECOG 0–1) - Your blood counts, liver, and kidney function are adequate - You do not have active autoimmune disease - You have not previously received anti-PD-1 immunotherapy **You may NOT be eligible if...** - You have evidence of interstitial lung disease or active pneumonitis - You have an active serious infection - You have another invasive cancer diagnosed in the last 5 years - You have a known history of HIV, active hepatitis B or C, or active tuberculosis - You are pregnant, breastfeeding, or planning pregnancy during the trial - You have psychiatric conditions or substance abuse that would prevent compliance Talk to your doctor to see if this trial is right for you.